Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin + SGLT2 inhibitor + liraglutide versus other triple oral antidiabetic regimens in poorly controlled type 2 diabetes
ChiCTR2500097727Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Feb 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metformin, dapagliflozin and liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Glycosylated hemoglobin. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500097727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097727.